Head and neck cancers (HNCs) are a heterogeneous group consisting of cancers of the mouth, including the lip, tongue, gum, floor of mouth, palate, and other parts of mouth (ICD-10 code = C00-C06),; the salivary glands (ICD-10 code = C07-C08); the pharynx, including the tonsil, oropharynx, nasopharynx, pyriform fossa, hypopharynx, other mouth/pharynx (ICD-10 code = C09-C14); the nose, sinuses, and related structures (ICD-10 code = C30-C31), and the larynx (ICD-10 code = C32) (World Health Organization, 2011). HNCs usually begin in the squamous cells that line the moist mucosal surfaces of the tissues and organs of the head and neck. It is estimated that more than 80% of all oral cavity and pharynx cancers are squamous cell carcinomas (Howlader et al., 2020; National Cancer Institute, 2021).
In the 8MM, the diagnosed incident cases of HNC are expected to increase from 279,734 cases in 2020 to 338,790 cases in 2030, at an Annual Growth Rate (AGR) of 2.11%. In 2030, urban China will have the highest number of diagnosed incident cases of HNC in the 8MM, with 141,960 diagnosed incident cases, whereas Italy will have the fewest diagnosed incident cases with 13,720 cases. In the 8MM, the five-year diagnosed prevalent cases of HNC are expected to increase from 836,755 cases in 2020 to 1,018,417 cases in 2030, at an AGR of 2.17%. The publisher epidemiologists attribute the increase in the five-year diagnosed prevalent cases and diagnosed incident cases of HNC to diagnosed incidence rate, regression trend analysis and survival rates, and population dynamics in each market.
In the 8MM, the diagnosed incident cases of HNC are expected to increase from 279,734 cases in 2020 to 338,790 cases in 2030, at an Annual Growth Rate (AGR) of 2.11%. In 2030, urban China will have the highest number of diagnosed incident cases of HNC in the 8MM, with 141,960 diagnosed incident cases, whereas Italy will have the fewest diagnosed incident cases with 13,720 cases. In the 8MM, the five-year diagnosed prevalent cases of HNC are expected to increase from 836,755 cases in 2020 to 1,018,417 cases in 2030, at an AGR of 2.17%. The publisher epidemiologists attribute the increase in the five-year diagnosed prevalent cases and diagnosed incident cases of HNC to diagnosed incidence rate, regression trend analysis and survival rates, and population dynamics in each market.
Scope
This report provides an overview of the risk factors, comorbidities, and the global and historical trends for HNCs in the eight major markets (8MM: US, France, Germany, Italy, Spain, UK, Japan, and urban China). The report provides a 10-year epidemiological forecast of the diagnosed incident cases of HNCs. In this analysis, HNCs are grouped into the following groups:
- Cancers of the lip, oral cavity, pharynx, and larynx cancer (ICD-10 = C00-C06, C09, C12-C14, C32, and C10 [HPV-]); Oropharynx cancer (ICD-10 = C10); Nasopharynx cancer (ICD-10 = C11); Other HNC sites-salivary gland and nose, sinuses, and other related structures’ cancer (ICD-10 = C07-C08 and C30-C31).
- Each of the four groups is further segmented by risk factor (tobacco smoking history), histology distribution (squamous cell and non-squamous cell), and clinical stage at diagnosis among the squamous cell carcinomas. In addition, the diagnosed incident cases of oropharynx cancer were further segmented by risk factor (human papillomavirus infection status HPV+ and HPV-) and the diagnosed incident cases nasopharynx cancer were segmented by the risk factor of Epstein Barr virus infection (EBV+). The report provides a 10-year epidemiological forecast of the five-year diagnosed prevalent cases of each of the four groups.
- The HNC epidemiology report is written and developed by Masters- and PhD-level epidemiologists.
- The Epidemiology Report is in-depth, high quality, transparent and market-driven, providing expert analysis of disease trends in the 8MM.
Reasons to Buy
The HNCs Epidemiology series will allow you to:
- Develop business strategies by understanding the trends shaping and driving the global HNCs market.
- Quantify patient populations in the global HNCs market to improve product design, pricing, and launch plans.
- Organize sales and marketing efforts by identifying the age groups that present the best opportunities for HNCs therapeutics in each of the markets covered.
- Understand magnitude of HNCs by stage at diagnosis, risk factors, EGFR mutation, PD-L1 expression by CPS scores, and surgical and radiotherapy vs. systemic treatment.
Table of Contents
1 Head and Neck Squamous Cell Carcinoma: Executive Summary
2 Epidemiology
3 Appendix
List of Tables
List of Figures
